Acquired Immune Deficiency Syndrome
Conditions
Interventions
Treatment group:Highly Active Antiretroviral Therapy and Haoqin Qingdan Granules
Control group:single Highly Active Antiretroviral Therapy
Sponsors
China Academy of Chinese Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1) Age range from 18 to 65 years old, regardless of gender; 2) HIV antibody positive, confirmed by Western Blot confirmation test; 3) Received Highly Active Antiretroviral Therapy for = 5 years and had a plasma HIV load of<50 copies/ml for more than 18 months; 4) The CD4+T lymphocyte count ranges between 200 cells/ul and 300 cells/ul; 5) Meets the diagnostic criteria for damp heat internal accumulation syndrome 6)Volunteer to participate in this study and sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1) Severe Opportunistic infection was not controlled before enrollment; 2) Patients who participated in clinical trials of other drugs within one month prior to enrollment; 3) Individuals who received immunomodulatory therapy within one month prior to enrollment; 4) White Blood Cell < 2 × 109/L, Neutrophil count < 1.0 × 109/L, Hemoglobin < 90g/L, Platelet < 75 × 109/L, liver and kidney dysfunction (liver dysfunction refers to Aspartate transaminase , Alaninetransaminase, or total bilirubin = 2 times the upper limit of the reference value, and kidney dysfunction refers to creatinine clearance rate below the normal value) 5) Pregnant or lactating women, or women preparing for pregnancy; 6) Merge with other serious diseases (such as tumors, liver cirrhosis, cardiovascular and cerebrovascular diseases, etc.); 7) Patients with intellectual or language impairments who are unable to fully understand the experimental content or provide good cooperation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| T Cell Receptor Rearrangement Excision Circle;Immune reconstruction efficiency; | — |
Secondary
| Measure | Time frame |
|---|---|
| CD8+T lymphocytes;CD4+T lymphocytes;CD4+CD45RA+IL-7R;Tumor Necrosis Factor-a;Interleukin-7;Interleukin-2;T helper cell 17;clinical symptoms;Lipopolysaccharide;insulin-like growth factor 1;thymopoietin II; Interleukin-6;CD4+/CD8+ratio;Thymosin a;thymus index;growth hormone;CD4+CD25+CD45RO+;CD4+CD25+CD45RA+; | — |
Countries
China
Contacts
Public ContactJipeng Dong,Jian Wang
China Academy of Chinese Medical Sciences
Outcome results
None listed